1 / 16

Efficient Integration of IRB Activities with Institutional Processes for Effective Research Compliance

This article examines the efficiency and effectiveness of Institutional Review Boards (IRBs) in integrating their activities with various institutional processes such as senior administration, research HIPAA privacy policies, conflict of interest policies, and more. It explores how IRBs can enhance their value to the institution, provide sufficient expertise, and engage in collaborative problem-solving. Additionally, it discusses the integration of HIPAA privacy concerns, local protection processes, and conflict of interest policies in IRB activities. The article also addresses the responsibility of patients for trial costs and medical care for adverse consequences in informed consent documents. Relevant AAMC reports and considerations for clinical trial contracts are highlighted.

tereasab
Download Presentation

Efficient Integration of IRB Activities with Institutional Processes for Effective Research Compliance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Are IRBs Efficient, Effective, or Redundant? David C. Clark, Ph.D. Director, Research Compliance Rush University Center

  2. Efficient IRBs integrate their activities with... • Senior Administration • Research HIPAA Privacy policies • Other local protection processes • Conflict of Interest policies and Committee • Clinical trial contract office • Investigator clinical trial budgets

  3. Relationship with Senior Administration • Reinforcement of IRB’s value to the Institution • Recognition for IRB service • Sufficient expertise on the IRB • Provision of adequate non-human resources • Long-term planning with the IRB • Collaborative problem-solving

  4. Integrating HIPAA Privacy concerns • Criteria for “Waiver of Authorization” • Criteria for “de-identification” of all data • Accessing clinical information to recruit for clinical trials • Re-use of data stored in data/tissue repositories

  5. Integrating other local protection processes • Radiation Safety Committee (licensed by NRC) • Radioactive Drug Research Committee (21 CFR 361.1) • Institutional Biosafety Committee

  6. Integrating Conflict of Interest / Individual • Institutional and IRB policies • Ability to bring data about financial relationships to bear on specific studies in timely manner • Communication between Conflict of Interest Committee and IRB

  7. Integrating Conflict of Interest / Institutional • Institutional and IRB policies • Ability to bring data about financial relationships to bear on specific studies in timely manner • Communication between Conflict of Interest Committee and IRB • Objectivity is more difficult

  8. Two relevant AAMC Reports Protecting Subjects, Preserving Trust, Promoting Progress I: Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research • AAMC, December 2001 • Task Force on Financial Conflicts of Interest in Clinical Research

  9. Two relevant AAMC Reports Protecting Subjects, Preserving Trust, Promoting Progress II: Principles and Recommendations for Oversight of an Institution's Financial Interests in Human Subjects Research • AAMC, October 2002 • Task Force on Financial Conflicts of Interest in Clinical Research

  10. INFORMED CONSENT DOCUMENTS:Patient’s responsibility for trial costs • the following elements of information shall also be provided to each subject: (3) Any additional costs to the subject that may result from participation in the research. (FDA) 21 CFR 50.25.b.3

  11. INFORMED CONSENT DOCUMENTS:Patient’s responsibility for trial costs • Should “costs to my insurance company” be considered “costs to me?” • I pay the insurance premiums • I pay the deductibles, co-pays, and remainders • My insurance expenses (today) sometimes limit my access to future insurance coverage • If my insurance doesn’t pay, I could get stuck with a very large bill

  12. INFORMED CONSENT DOCUMENTS:Medical care for adverse consequences • (Issue:) Does fault lie with product/participation or with Investigator? • “Contract should contain prohibition against billing of patient’s insurer.” • “Sponsors should not place dollar caps on medical treatment for adverse consequences.”

  13. INFORMED CONSENT DOCUMENTS:Patient’s responsibility for trial costs • “In no case should Sponsors require the Institution to bill the cost of subject’s injury that is a consequence of trial participation to the subject’s insurance company, then only pay for what is NOT covered by insurance.” • “Ethically unacceptable.” AAMC, January 2004

  14. New AAMC Report Clinical Trial Contracts: A Discussion of Four Selected Provisions • AAMC, January 2004 • Baer, Feiler, Regulski, and Switzer

  15. INFORMED CONSENT DOCUMENTS:Patient’s responsibility for trial costs • Contract or practice that seeks to bill subject’s insurance company (and requires documentation of “failure to pay”) before Sponsor assumes any responsibility for expenses -- is this ethical? • Some patients pay via insurance premiums and co-pays while others do not -- is this equitable? • Means of including patients and providing clinical care to those who otherwise could not afford.

More Related